Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15517534 | 0.78 | CES2 (0.33) | CES2CES1MAOBRIPK1 | |
| SCHEMBL27872417 | 0.78 | HDAC1 (0.35) | — | |
| SCHEMBL16105773 | 0.75 | CES2 (0.39) | CES2CES1MAOBRIPK1 | |
| SCHEMBL16105658 | 0.75 | CES2 (0.39) | CES2CES1MAOBRIPK1 | |
| SCHEMBL12474303 | 0.74 | CES2 (0.31) | CES2CES1 | |
| SCHEMBL28720334 | 0.74 | TAAR1 (0.32) | — | |
| SCHEMBL28773066 | 0.74 | DAO (0.42) | — | |
| SCHEMBL28713398 | 0.74 | — | — | |
| SCHEMBL29277289 | 0.74 | — | — | |
| SCHEMBL1239272 | 0.73 | CES2 (0.38) | CES2CES1MAOBRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532663-B1 | Naphthalenetetracarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2016-03-16 | — | — | EP | claimed |
| EP-2532663-A1 | Naphthalenecarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2012-12-12 | — | — | EP | claimed |
| EP-1599201-B1 | SELECTIVE NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-04-14 | — | — | EP | claimed |
| US-7411073-B2 | Selective non-steroidal glucocorticoid receptor modulators | MERCK & CO., INC. (US) | 2008-08-12 | — | — | US | claimed |
| US-20060074120-A1 | cyclopent[f]pyrazole derivatives; antiinflammatory agent; autoimmune diseases; side effect reduction, advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity or metabolism | MERCK SHARP & DOHME CORP. | 2006-04-06 | — | — | US | claimed |
| JP-10168002-A | — | — | None | — | — | JP | disclosed |
| JP-10168002-A | — | — | None | — | — | JP | disclosed |
| WO-2023246009-A1 | OLEFIN POLYMERIZATION METALLOCENE CATALYST COMPOSITION, PREPARATION THEREOF AND USE THEREOF | 中国石油天然气股份有限公司 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023240961-A1 | ETHYLENE-PROPYLENE COPOLYMERIZATION CATALYST COMPOSITION, AND PREPARATION AND USE THEREOF | 中国石油天然气股份有限公司 | 2023-12-21 | — | — | WO | disclosed |
| EP-3424903-B1 | METHOD FOR PRODUCING SULFOXIDE DERIVATIVE | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2021-09-29 | — | — | EP | disclosed |
| CN-108779067-B | Process for producing sulfoxide derivative | 组合化学工业株式会社 | 2020-07-14 | — | — | CN | disclosed |
| CN-105985368-B | Metallocene complex containing heteroatom pi-ligand, its preparation method, its catalyst system and application of catalyst system | 中国石油天然气股份有限公司 | 2020-03-10 | — | — | CN | disclosed |
| US-20080017850-A1 | applying n-type organic semiconducting compound 1,6,7,12-Tetrachloro-N,N'-benzyl-perylene-3,9; 11,12-tetracarboxylic diimide or 1,6,7,12-tetrachloroperylen-3,9; 9,10-tetracarboxylic dianhydride; charge transfer compounds for electronics, optoelectronics and photonic applications; chemical intermediates | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-24 | — | — | US | disclosed |
| WO-2007128774-A1 | METHOD FOR PRODUCING ORGANIC FIELD-EFFECT TRANSISTORS | BASF SE (DE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259475-A1 | METHOD FOR PRODUCING ORGANIC FIELD-EFFECT TRANSISTORS | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-08 | — | — | US | disclosed |
| WO-2007093643-A1 | FLUORINATED RYLENETETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007074137-A1 | NAPHTHALENETETRACARBOXYLIC ACID DERIVATIVES AND THEIR USE AS SEMICONDUCTORS | BASF SE (DE) | 2007-07-05 | — | — | WO | disclosed |
| US-20060074120-A1 | cyclopent[f]pyrazole derivatives; antiinflammatory agent; autoimmune diseases; side effect reduction, advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity or metabolism | MERCK SHARP & DOHME CORP. | 2006-04-06 | — | — | US | disclosed |
| JP-H10168002-A | PRODUCTION OF LIQUID CRYSTAL COMPOUND HAVING 2-(3,4,5-TRIFLUOROPHENYL)ETHYL GROUP | CHISSO CORP | 1998-06-23 | — | — | JP | disclosed |
| JP-H10168002-A | PRODUCTION OF LIQUID CRYSTAL COMPOUND HAVING 2-(3,4,5-TRIFLUOROPHENYL)ETHYL GROUP | CHISSO CORP | 1998-06-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080017850-A1 | applying n-type organic semiconducting compound 1,6,7,12-Tetrachloro-N,N'-benzyl-perylene-3,9; 11,12-tetracarboxylic diimide or 1,6,7,12-tetrachloroperylen-3,9; 9,10-tetracarboxylic dianhydride; charge transfer compounds for electronics, optoelectronics and photonic applications; chemical intermediates | POF1B, NR2C2, NR2E1 | CES2 2212/4885CES1 3366/4885MAOB 1616/4885 |
| US-20060074120-A1 | cyclopent[f]pyrazole derivatives; antiinflammatory agent; autoimmune diseases; side effect reduction, advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity or metabolism | NR3C1, NR3C2, NR5A1 | CES2 4212/4885CES1 453/4885MAOB 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.